Japan changed important parts of its clinical development system in December 2023, when the Ministry of […]
Daiichi Sankyo has built one of the pharmaceutical industry’s most productive antibody-drug conjugate platforms. Enhertu has […]
Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to […]
Japan’s pharmaceutical ecosystem is seemingly undergoing a profound structural shift. If you are targeting the Japanese […]
The biopharma world is still processing the seismic news of Isomorphic Labs’ $2.1 billion Series B […]
Japan’s pharmaceutical pricing system is often seen as a local matter. It is discussed in terms […]
The Easy Hurdle That Kills Programs A drug candidate can clear the standard off-target panel and […]
Japan is no longer a market foreign medical device companies can afford to treat as “difficult […]
Japan is one of the world’s most demanding healthcare markets. It is also one of the […]
Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]